{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:06:45Z","timestamp":1790644005743,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003653","name":"Korean National Institute of Health","doi-asserted-by":"crossref","award":["2025-E1903-00"],"award-info":[{"award-number":["2025-E1903-00"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003653","name":"Korean National Institute of Health","doi-asserted-by":"crossref","award":["2025-E1903-00"],"award-info":[{"award-number":["2025-E1903-00"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003653","name":"Korean National Institute of Health","doi-asserted-by":"crossref","award":["2025-E1903-00"],"award-info":[{"award-number":["2025-E1903-00"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ILDONG Pharmaceutical, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-13456-8","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T15:18:55Z","timestamp":1756480735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis B"],"prefix":"10.1038","volume":"15","author":[{"given":"Jae Seung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Lim","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Ju","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Seok","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Joon","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Kul","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisu","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Na","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Gyune","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Up","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"13456_CR1","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3350\/cmh.2022.0342","volume":"29","author":"CL Lin","year":"2023","unstructured":"Lin, C. L. & Kao, J. H. Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection. Clin. Mol. Hepatol. 29, 605\u2013622. https:\/\/doi.org\/10.3350\/cmh.2022.0342 (2023).","journal-title":"Clin. Mol. Hepatol."},{"key":"13456_CR2","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","volume":"64","author":"M Levrero","year":"2016","unstructured":"Levrero, M. & Zucman-Rossi, J. Mechanisms of HBV-induced hepatocellular carcinoma. J. Hepatol. 64, S84-s101. https:\/\/doi.org\/10.1016\/j.jhep.2016.02.021 (2016).","journal-title":"J. Hepatol."},{"key":"13456_CR3","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67, 1560\u20131599. https:\/\/doi.org\/10.1002\/hep.29800 (2018).","journal-title":"Hepatology"},{"issue":"370\u2013398","key":"13456_CR4","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"EASL","year":"2017","unstructured":"EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J. Hepatol. 67(370\u2013398), 2017. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021 (2017).","journal-title":"J. Hepatol."},{"key":"13456_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin, S. K. et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol. Int. 10, 1\u201398. https:\/\/doi.org\/10.1007\/s12072-015-9675-4 (2016).","journal-title":"Hepatol. Int."},{"key":"13456_CR6","doi-asserted-by":"publisher","unstructured":"KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 25 93\u2013159 https:\/\/doi.org\/10.3350\/cmh.2019.1002 (2019).","DOI":"10.3350\/cmh.2019.1002"},{"key":"13456_CR7","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3350\/cmh.2022.0420","volume":"29","author":"YC Hsu","year":"2023","unstructured":"Hsu, Y. C., Tseng, C. H. & Kao, J. H. Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm. Clin. Mol. Hepatol. 29, 869\u2013890. https:\/\/doi.org\/10.3350\/cmh.2022.0420 (2023).","journal-title":"Clin. Mol. Hepatol."},{"key":"13456_CR8","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3350\/cmh.2020.0012","volume":"26","author":"SB Lee","year":"2020","unstructured":"Lee, S. B. et al. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir. Clin. Mol. Hepatol. 26, 364\u2013375. https:\/\/doi.org\/10.3350\/cmh.2020.0012 (2020).","journal-title":"Clin. Mol. Hepatol."},{"key":"13456_CR9","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/hep.26301","volume":"58","author":"GL Wong","year":"2013","unstructured":"Wong, G. L. et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 58, 1537\u20131547. https:\/\/doi.org\/10.1002\/hep.26301 (2013).","journal-title":"Hepatology"},{"key":"13456_CR10","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1080\/14656566.2021.1967321","volume":"22","author":"JE Song","year":"2021","unstructured":"Song, J. E. & Park, J. Y. Besifovir dipivoxil maleate: A novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B. Expert Opin. Pharmacother. 22, 2427\u20132433. https:\/\/doi.org\/10.1080\/14656566.2021.1967321 (2021).","journal-title":"Expert Opin. Pharmacother."},{"key":"13456_CR11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3350\/cmh.2020.0307","volume":"27","author":"DS Song","year":"2021","unstructured":"Song, D. S. et al. Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial. Clin. Mol. Hepatol. 27, 346\u2013359. https:\/\/doi.org\/10.3350\/cmh.2020.0307 (2021).","journal-title":"Clin. Mol. Hepatol."},{"key":"13456_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/jgh.15710","volume":"37","author":"HJ Yim","year":"2022","unstructured":"Yim, H. J. et al. Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients. J. Gastroenterol. Hepatol. 37, 378\u2013386. https:\/\/doi.org\/10.1111\/jgh.15710 (2022).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"13456_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16050887","author":"HJ Yim","year":"2024","unstructured":"Yim, H. J. et al. Reduced risk of hepatocellular carcinoma in patients with chronic hepatitis b receiving long-term besifovir therapy. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers16050887 (2024).","journal-title":"Cancers (Basel)"},{"key":"13456_CR14","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.1038\/s41598-025-89325-1","volume":"15","author":"H Kim","year":"2025","unstructured":"Kim, H. et al. Comparison of hepatocellular carcinoma incidence after long-term treatment with besifovir vs tenofovir AF. Sci. Rep. 15, 5637. https:\/\/doi.org\/10.1038\/s41598-025-89325-1 (2025).","journal-title":"Sci. Rep."},{"key":"13456_CR15","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1002\/cncr.29537","volume":"121","author":"WR Kim","year":"2015","unstructured":"Kim, W. R. et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer 121, 3631\u20133638. https:\/\/doi.org\/10.1002\/cncr.29537 (2015).","journal-title":"Cancer"},{"key":"13456_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/hep.26180","volume":"58","author":"T Hosaka","year":"2013","unstructured":"Hosaka, T. et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58, 98\u2013107. https:\/\/doi.org\/10.1002\/hep.26180 (2013).","journal-title":"Hepatology"},{"key":"13456_CR17","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1177\/135965350601100806","volume":"11","author":"MF Yuen","year":"2006","unstructured":"Yuen, M. F. et al. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir. Ther. 11, 977\u2013983 (2006).","journal-title":"Antivir. Ther."},{"key":"13456_CR18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.5009\/gnl220390","volume":"18","author":"TH Kim","year":"2024","unstructured":"Kim, T. H. et al. Noninferiority outcomes of besifovir compared to tenofovir alafenamide in treatment-na\u00efve patients with chronic hepatitis B. Gut Liver 18, 305\u2013315. https:\/\/doi.org\/10.5009\/gnl220390 (2024).","journal-title":"Gut Liver"},{"key":"13456_CR19","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jhep.2019.03.028","volume":"71","author":"SU Kim","year":"2019","unstructured":"Kim, S. U. et al. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-na\u00efve chronic hepatitis B in South Korea. J. Hepatol. 71, 456\u2013464. https:\/\/doi.org\/10.1016\/j.jhep.2019.03.028 (2019).","journal-title":"J. Hepatol."},{"key":"13456_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","volume":"5","author":"J Choi","year":"2019","unstructured":"Choi, J. et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: A Korean nationwide cohort study. JAMA Oncol. 5, 30\u201336. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4070 (2019).","journal-title":"JAMA Oncol."},{"key":"13456_CR21","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1136\/gutjnl-2023-330225","volume":"73","author":"WM Choi","year":"2024","unstructured":"Choi, W. M. et al. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B. Gut 73, 649\u2013658. https:\/\/doi.org\/10.1136\/gutjnl-2023-330225 (2024).","journal-title":"Gut"},{"key":"13456_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhep.2023.09.011","volume":"80","author":"HS Chun","year":"2024","unstructured":"Chun, H. S. et al. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B. J. Hepatol. 80, 20\u201330. https:\/\/doi.org\/10.1016\/j.jhep.2023.09.011 (2024).","journal-title":"J. Hepatol."},{"key":"13456_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12072-019-09997-6","volume":"14","author":"J Zhao","year":"2020","unstructured":"Zhao, J. et al. TAF and TDF attenuate liver fibrosis through NS5ATP9, TGF\u03b21\/Smad3, and NF-\u03baB\/NLRP3 inflammasome signaling pathways. Hepatol. Int. 14, 145\u2013160. https:\/\/doi.org\/10.1007\/s12072-019-09997-6 (2020).","journal-title":"Hepatol. Int."},{"key":"13456_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261067","volume":"16","author":"SW Lee","year":"2021","unstructured":"Lee, S. W. et al. Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K\/Akt\/mTOR signaling pathway. PLoS ONE 16, e0261067. https:\/\/doi.org\/10.1371\/journal.pone.0261067 (2021).","journal-title":"PLoS ONE"},{"key":"13456_CR25","doi-asserted-by":"publisher","first-page":"8161","DOI":"10.1038\/s41598-024-58807-z","volume":"14","author":"J Zhao","year":"2024","unstructured":"Zhao, J. et al. TDF and TAF inhibit liver cancer cell migration, invasion via p7TP3. Sci. Rep. 14, 8161. https:\/\/doi.org\/10.1038\/s41598-024-58807-z (2024).","journal-title":"Sci. Rep."},{"key":"13456_CR26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/jgh.16178","volume":"38","author":"K Murata","year":"2023","unstructured":"Murata, K. & Mizokami, M. Possible biological mechanisms of entecavir versus tenofovir disoproxil fumarate on reducing the risk of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 38, 683\u2013691. https:\/\/doi.org\/10.1111\/jgh.16178 (2023).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"13456_CR27","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/gutjnl-2013-305138","volume":"63","author":"CL Lai","year":"2014","unstructured":"Lai, C. L. et al. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut 63, 996\u20131004. https:\/\/doi.org\/10.1136\/gutjnl-2013-305138 (2014).","journal-title":"Gut"},{"key":"13456_CR28","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/ijc.20636","volume":"113","author":"B Chang","year":"2005","unstructured":"Chang, B., Nishikawa, M., Nishiguchi, S. & Inoue, M. L-carnitine inhibits hepatocarcinogenesis via protection of mitochondria. Int. J. Cancer 113, 719\u2013729. https:\/\/doi.org\/10.1002\/ijc.20636 (2005).","journal-title":"Int. J. Cancer"},{"key":"13456_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/hc9.0000000000000425","author":"J Lyu","year":"2024","unstructured":"Lyu, J. et al. Potential utility of l-carnitine for preventing liver tumors derived from metabolic dysfunction-associated steatohepatitis. Hepatol. Commun. https:\/\/doi.org\/10.1097\/hc9.0000000000000425 (2024).","journal-title":"Hepatol. Commun."},{"key":"13456_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100627","volume":"9","author":"H Ishikawa","year":"2014","unstructured":"Ishikawa, H. et al. L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway. PLoS ONE 9, e100627. https:\/\/doi.org\/10.1371\/journal.pone.0100627 (2014).","journal-title":"PLoS ONE"},{"key":"13456_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/nu14234999","author":"T Liu","year":"2022","unstructured":"Liu, T. et al. The association of serum L-carnitine concentrations with the risk of cancer in chinese adults with hypertension. Nutrients https:\/\/doi.org\/10.3390\/nu14234999 (2022).","journal-title":"Nutrients"},{"key":"13456_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020282","author":"JC Kim","year":"2022","unstructured":"Kim, J. C. et al. Identification and characterization of besifovir-resistant hepatitis B virus isolated from a chronic hepatitis B patient. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines10020282 (2022).","journal-title":"Biomedicines"},{"key":"13456_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071637","author":"J Won","year":"2022","unstructured":"Won, J. et al. Susceptibility of drug resistant hepatitis B virus mutants to besifovir. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines10071637 (2022).","journal-title":"Biomedicines"},{"key":"13456_CR34","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3350\/cmh.2020.0049","volume":"26","author":"HJ Yim","year":"2020","unstructured":"Yim, H. J. et al. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin. Mol. Hepatol. 26, 411\u2013429. https:\/\/doi.org\/10.3350\/cmh.2020.0049 (2020).","journal-title":"Clin. Mol. Hepatol."},{"key":"13456_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3350\/cmh.2019.0010n","volume":"26","author":"KASL clinical practice guidelines for liver cirrhosis","year":"2020","unstructured":"KASL clinical practice guidelines for liver cirrhosis. Varices, hepatic encephalopathy, and related complications. Clin. Mol. Hepatol. 26, 83\u2013127. https:\/\/doi.org\/10.3350\/cmh.2019.0010n (2020).","journal-title":"Clin. Mol. Hepatol."},{"key":"13456_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3350\/cmh.2016.0059","volume":"23","author":"G Kim","year":"2017","unstructured":"Kim, G., Kim, M. Y. & Baik, S. K. Transient elastography versus hepatic venous pressure gradient for diagnosing portal hypertension: A systematic review and meta-analysis. Clin. Mol. Hepatol. 23, 34\u201341. https:\/\/doi.org\/10.3350\/cmh.2016.0059 (2017).","journal-title":"Clin. Mol. Hepatol."},{"key":"13456_CR37","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3109\/23744235.2016.1165860","volume":"48","author":"J Chen","year":"2016","unstructured":"Chen, J. et al. Controlled attenuation parameter for the detection of hepatic steatosis in patients with chronic hepatitis B. Infect Dis. (Lond) 48, 670\u2013675. https:\/\/doi.org\/10.3109\/23744235.2016.1165860 (2016).","journal-title":"Infect Dis. (Lond)"},{"key":"13456_CR38","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach, J. K. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67, 358\u2013380. https:\/\/doi.org\/10.1002\/hep.29086 (2018).","journal-title":"Hepatology"},{"key":"13456_CR39","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"EASL Clinical Practice Guidelines","year":"2018","unstructured":"EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J. Hepatol. 69, 182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019 (2018).","journal-title":"J. Hepatol."},{"key":"13456_CR40","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3350\/cmh.2020.0004","volume":"26","author":"S Lee","year":"2020","unstructured":"Lee, S., Kim, S. S., Chang, D. R., Kim, H. & Kim, M. J. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Clin. Mol. Hepatol. 26, 340\u2013351. https:\/\/doi.org\/10.3350\/cmh.2020.0004 (2020).","journal-title":"Clin. Mol. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13456-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13456-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13456-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:25:56Z","timestamp":1774337156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13456-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13456"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13456-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"3 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: In the original version of this Article the Acknowledgements section was incomplete. The Acknowledgements section now reads \u201cThis study was supported by the National Institute of Health (NIH) (2025-E1903-00) and Soonchunhyang University Research Fund. Funding acquisition: SU Kim and SG Kim.\u201d The original Article has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31879"}}